Biomedical Evaluation and Toxicity of Polymeric Nanomedicines
- By Constantin V. Uglea1
-
View Affiliations Hide Affiliations1 “Grigore T. Popa” University of Medicine and Pharmacy Iasi, Department of Medical Bioengineering, Universitatii Str., no. 16, 700115 Iasi, Romania
- Source: Polymeric Nanomedicines , pp 119-143
- Publication Date: May 2013
- Language: English
Biomedical Evaluation and Toxicity of Polymeric Nanomedicines, Page 1 of 1
< Previous page | Next page > /docserver/preview/fulltext/9781608054848/chapter-3-1.gif
On 17 January 2007, the European Group of Ethics (EGE) issued a draft report that recognized the potential of nanomedicine in terms of developing new diagnostics and therapies (http://ec.europa.eu/european _group_ethics/activities /ethics_en.htm). The group proposes that measures be established to verify the safety of nanomedical products and devices, and calls on the relevant authorities to carry out a proper assessment of the risks and safety of nanomedicine. This chapter deals with toxicological aspects of various nanoparticles such as polymer-drug conjugates, carbon nanotubes, quantum dots, dendrimers and other various nanostructures. The nanoparticle-biological organism interactions and immunological risk of the nanoparticles are also examined in this chapter.
-
From This Site
/content/books/9781608054848.chapter-3dcterms_subject,pub_keyword-contentType:Journal -contentType:Figure -contentType:Table -contentType:SupplementaryData105
